866-997-4948(US-Canada Toll Free)

Bone Marrow Transplant Rejection - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Mar 2017

Category :

Pharmaceutical

No. of Pages : 455 Pages

Bone Marrow Transplant Rejection - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H1 2017, provides an overview of the Bone Marrow Transplant Rejection (Immunology) pipeline landscape.

Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain and shortness of breath. Treatment includes immunosuppressive drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Marrow Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 26, 16, 1, 35, 6 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 13 and 3 molecules, respectively.

Bone Marrow Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection (Immunology).
- The pipeline guide reviews pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bone Marrow Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bone Marrow Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bone Marrow Transplant Rejection (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Bone Marrow Transplant Rejection - Overview 11
Bone Marrow Transplant Rejection - Therapeutics Development 12
Pipeline Overview 12
Pipeline by Companies 13
Pipeline by Universities/Institutes 19
Products under Development by Companies 22
Products under Development by Universities/Institutes 28
Bone Marrow Transplant Rejection - Therapeutics Assessment 30
Assessment by Target 30
Assessment by Mechanism of Action 35
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Bone Marrow Transplant Rejection - Companies Involved in Therapeutics Development 44
AbbVie Inc 44
AbGenomics International Inc 44
Actelion Ltd 45
Alexion Pharmaceuticals Inc 45
Allergan Plc 46
Amunix Operating Inc 46
AnaptysBio Inc 47
apceth Biopharma GmbH 47
Aptevo Therapeutics Inc 48
arGEN-X BV 48
Athersys Inc 49
Bellicum Pharmaceuticals Inc 49
Bio-Cancer Treatment International Ltd 50
Biogen Inc 50
Bristol-Myers Squibb Company 51
Cantex Pharmaceuticals Inc 51
Capricor Therapeutics Inc 52
Cell Source Inc 52
Cell2B Advanced Therapeutics SA 53
CellECT Bio Inc 53
Cleveland BioLabs Inc 54
Compugen Ltd 54
Cynata Therapeutics Limited 55
Cytodyn Inc 55
Dompe Farmaceutici SpA 56
Dr. Falk Pharma GmbH 56
Escape Therapeutics Inc 57
F. Hoffmann-La Roche Ltd 57
Fate Therapeutics Inc 58
Generon (Shanghai) Corp Ltd 58
Gilead Sciences Inc 59
GlaxoSmithKline Plc 59
Immunomedics Inc 60
Incyte Corp 60
Jazz Pharmaceuticals Plc 61
Kadmon Corp LLC 61
Kamada Ltd 62
Kiadis Pharma NV 62
Kymab Ltd 63
Kyorin Pharmaceutical Co Ltd 63
MacroGenics Inc 64
Mallinckrodt Plc 64
Medsenic 65
Mesoblast Ltd 65
Millennium Pharmaceuticals Inc 66
Nektar Therapeutics 66
Neovii Pharmaceuticals AG 67
Nohla Therapeutics Inc 67
Novartis AG 68
OncoImmune Inc 68
OSE Immunotherapeutics 69
Pfizer Inc 69
Pharmicell Co Ltd 70
Pluristem Therapeutics Inc 70
REGiMMUNE Corp 71
Sanofi 71
Sarepta Therapeutics Inc 72
Seattle Genetics Inc 72
Seres Therapeutics Inc 73
Sigmoid Pharma Ltd 73
Synedgen Inc 74
Taiga Biotechnologies Inc 74
Takeda Pharmaceutical Company Ltd 75
Targazyme Inc 75
United BioPharma Inc 76
Vault Pharma Inc 76
VBI Vaccines Inc 77
Xenikos BV 77
XL-protein GmbH 78
ZIOPHARM Oncology Inc 78
Bone Marrow Transplant Rejection - Drug Profiles 79
abatacept - Drug Profile 79
AbGn-168H - Drug Profile 87
AGS-499 - Drug Profile 89
aldesleukin - Drug Profile 90
Alecmestencel-L - Drug Profile 92
alpha-1 proteinase inhibitor (human) - Drug Profile 93
ALXN-1007 - Drug Profile 99
AMX-342 - Drug Profile 101
anti-thymocyte globulin (rabbit) - Drug Profile 102
Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile 104
ARGX-115 - Drug Profile 105
arsenic trioxide - Drug Profile 106
ATIR-101 - Drug Profile 107
BCT-200 - Drug Profile 112
begelomab - Drug Profile 113
Biologic to Activate IL-2 for Graft Versus Host Disease - Drug Profile 114
Biologics for Graft Versus Host Disease - Drug Profile 115
bortezomib - Drug Profile 116
brentuximab vedotin - Drug Profile 124
budesonide - Drug Profile 151
C-87 - Drug Profile 155
cannabidiol - Drug Profile 156
CAP-2003 - Drug Profile 159
CBLB-612 - Drug Profile 161
CD-24Fc - Drug Profile 163
Cell Therapy for Graft Versus Host Disease - Drug Profile 165
Cell Therapy for Graft-Versus Host Disease - Drug Profile 166
Cellgram for Graft Versus Host Disease - Drug Profile 167
Cellular Immunotherapy for Acute Graft Versus Host Disease - Drug Profile 168
Cellular Immunotherapy for Autoimmune Diseases and Transplantation - Drug Profile 169
Cellular Immunotherapy for Bone Marrow Transplantation - Drug Profile 171
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 172
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 173
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 174
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 175
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 176
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 177
Cellular Immunotherapy for Graft Versus Host Disease and Multiple Myeloma - Drug Profile 178
cenicriviroc mesylate - Drug Profile 179
CGEN-15001 - Drug Profile 187
CRCBT-080004 - Drug Profile 190
cyclosporine CR + cyclosporine IR - Drug Profile 191
CYP-001 - Drug Profile 192
defibrotide sodium - Drug Profile 194
dociparstat sodium - Drug Profile 203
Echinomycin - Drug Profile 205
entospletinib - Drug Profile 206
ENTXA-2 - Drug Profile 208
ES-210 - Drug Profile 209
F-652 - Drug Profile 210
FR-104 - Drug Profile 212
Ha-7 - Drug Profile 215
HE-33 - Drug Profile 216
ibrutinib - Drug Profile 217
ImmuneSafe - Drug Profile 246
ImmuStem - Drug Profile 247
INX-021 - Drug Profile 248
IT-603 - Drug Profile 250
IT-901 - Drug Profile 251
itacitinib adipate - Drug Profile 253
ixazomib citrate - Drug Profile 256
KD-025 - Drug Profile 266
KRP-203 - Drug Profile 271
KY-1005 - Drug Profile 273
MAX-16H5 - Drug Profile 274
MesoStem - Drug Profile 275
methoxsalen - Drug Profile 276
MGD-010 - Drug Profile 278
milatuzumab - Drug Profile 281
Monoclonal Antibody for Graft Versus Host Disease and Inflammation - Drug Profile 284
Monoclonal Antibody to Activate BTLA for GVHD - Drug Profile 285
Monoclonal Antibody to Inhibit T-Bet for Immunology and Oncology - Drug Profile 286
MPC-CBE - Drug Profile 287
natalizumab - Drug Profile 289
nilotinib - Drug Profile 294
NKTR-358 - Drug Profile 301
obinutuzumab - Drug Profile 302
OCU-300 - Drug Profile 310
Oligonucleotide to Inhibit NFAT1 for GVHD - Drug Profile 311
panobinostat - Drug Profile 312
PF-05285401 - Drug Profile 320
PLXR-18 - Drug Profile 332
ponesimod - Drug Profile 339
Preimplantation Factor - Drug Profile 342
PRO-140 - Drug Profile 344
ProTmune - Drug Profile 353
PTX-15 - Drug Profile 355
Recombinant Protein for Graft Versus Host Disease and Autoimmune Disorders - Drug Profile 356
Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis - Drug Profile 357
Recombinant Protein to Antagonize ILT3 for Graft Versus Host Disease - Drug Profile 358
remestemcel-L - Drug Profile 359
reparixin - Drug Profile 365
RGI-2001 - Drug Profile 368
rimiducid + rivogenlecleucel - Drug Profile 371
rituximab biobetter - Drug Profile 376
RO-2959 - Drug Profile 377
rovalpituzumab tesirine - Drug Profile 378
ruxolitinib phosphate - Drug Profile 380
S-Graft - Drug Profile 395
SER-155 - Drug Profile 396
sirolimus - Drug Profile 397
Small Molecule for Autoimmune Disorders, Graft Versus Host Disease and Hemophagocytic Lymphohistiocytosis - Drug Profile 399
Small Molecule to Agonize AhR for Type 1 Diabetes and Graft Versus Host Disease - Drug Profile 400
Small Molecules to Inhibit Perforin for Bone Marrow Transplantation - Drug Profile 401
Small Molecules to Inhibit SHIP1 for Oncology and Immunology - Drug Profile 402
Small Molecules to Selectively Inhibit ROCK2 for Autoimmune Disorders - Drug Profile 403
sonidegib phosphate - Drug Profile 404
Stem Cell Therapy for Genito Urinary System And Sex Hormone Diseases, Immunology, Metabolic Disorders, Oncology and Respiratory Disease - Drug Profile 409
SYGN-305 - Drug Profile 410
Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease - Drug Profile 411
T-Guard - Drug Profile 412
TBX-1400 - Drug Profile 414
TM-5509 - Drug Profile 415
TZ-101 - Drug Profile 416
vedolizumab - Drug Profile 419
VPI-101 - Drug Profile 426
XL-085 - Drug Profile 427
ZL-1101 - Drug Profile 428
Bone Marrow Transplant Rejection - Dormant Projects 429
Bone Marrow Transplant Rejection - Discontinued Products 433
Bone Marrow Transplant Rejection - Product Development Milestones 434
Featured News & Press Releases 434
Appendix 446
Methodology 446
Coverage 446
Secondary Research 446
Primary Research 446
Expert Panel Validation 446
Contact Us 446
Disclaimer 447

List of Tables
Number of Products under Development for Bone Marrow Transplant Rejection, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Bone Marrow Transplant Rejection - Pipeline by AbbVie Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by AbGenomics International Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Actelion Ltd, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Alexion Pharmaceuticals Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Allergan Plc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Amunix Operating Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by AnaptysBio Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by apceth Biopharma GmbH, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Aptevo Therapeutics Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by arGEN-X BV, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Athersys Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Bio-Cancer Treatment International Ltd, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Biogen Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Bristol-Myers Squibb Company, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Cantex Pharmaceuticals Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Capricor Therapeutics Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Cell Source Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Cell2B Advanced Therapeutics SA, H1 2017
Bone Marrow Transplant Rejection - Pipeline by CellECT Bio Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Cleveland BioLabs Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Compugen Ltd, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Cynata Therapeutics Limited, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Cytodyn Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Dompe Farmaceutici SpA, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Dr. Falk Pharma GmbH, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Escape Therapeutics Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Fate Therapeutics Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Generon (Shanghai) Corp Ltd, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Gilead Sciences Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by GlaxoSmithKline Plc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Immunomedics Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Incyte Corp, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Jazz Pharmaceuticals Plc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Kadmon Corp LLC, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Kamada Ltd, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Kiadis Pharma NV, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Kymab Ltd, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
Bone Marrow Transplant Rejection - Pipeline by MacroGenics Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Mallinckrodt Plc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Medsenic, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Mesoblast Ltd, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Nektar Therapeutics, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Neovii Pharmaceuticals AG, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Nohla Therapeutics Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Novartis AG, H1 2017
Bone Marrow Transplant Rejection - Pipeline by OncoImmune Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by OSE Immunotherapeutics, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Pfizer Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Pharmicell Co Ltd, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Pluristem Therapeutics Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by REGiMMUNE Corp, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Sanofi, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Sarepta Therapeutics Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Seattle Genetics Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Seres Therapeutics Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Sigmoid Pharma Ltd, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Synedgen Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Taiga Biotechnologies Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Targazyme Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by United BioPharma Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Vault Pharma Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by VBI Vaccines Inc, H1 2017
Bone Marrow Transplant Rejection - Pipeline by Xenikos BV, H1 2017
Bone Marrow Transplant Rejection - Pipeline by XL-protein GmbH, H1 2017
Bone Marrow Transplant Rejection - Pipeline by ZIOPHARM Oncology Inc, H1 2017
Bone Marrow Transplant Rejection - Dormant Projects, H1 2017
Bone Marrow Transplant Rejection - Dormant Projects, H1 2017 (Contd..1), H1 2017
Bone Marrow Transplant Rejection - Dormant Projects, H1 2017 (Contd..2), H1 2017
Bone Marrow Transplant Rejection - Dormant Projects, H1 2017 (Contd..3), H1 2017
Bone Marrow Transplant Rejection - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Bone Marrow Transplant Rejection, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *